CommentaryPublished 31 May 2021

4SCAR2.0 Treating Refractory B Cell Lymphomas: An advanced Technology Saves More Lives!

Authors: Cheng Jiao, Liyuan Sheng, Lung-Ji Chang

Medical Case Reports

Volume 7 · Issue 5 · Pages 183

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

CAR-T cell therapy represents an innovative and effective therapy forpatientswithrefractory/relapsed Bcellmalignancies. However, many limitations remain with the currently approved CAR-T products, including antigen escape, CAR-T exhaustion in vivo, significant toxicity, and high cost, to name a few.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.

Try:

More from this journal

The newest in Medical Case Reports.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMedical Case Reports
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Cheng Jiao”
  • BylineArticles whose byline prints “Liyuan Sheng”
  • BylineArticles whose byline prints “Lung-Ji Chang”